ATE451387T1 - Neue mit dem zelltod assoziierte proteine aus der thap familie und par4 verwandte signalwege, die bei der kontrolle von apoptosis involviert sind - Google Patents

Neue mit dem zelltod assoziierte proteine aus der thap familie und par4 verwandte signalwege, die bei der kontrolle von apoptosis involviert sind

Info

Publication number
ATE451387T1
ATE451387T1 AT02796602T AT02796602T ATE451387T1 AT E451387 T1 ATE451387 T1 AT E451387T1 AT 02796602 T AT02796602 T AT 02796602T AT 02796602 T AT02796602 T AT 02796602T AT E451387 T1 ATE451387 T1 AT E451387T1
Authority
AT
Austria
Prior art keywords
par4
apoptosis
cell death
control
signaling pathways
Prior art date
Application number
AT02796602T
Other languages
English (en)
Inventor
Jean-Philippe Girard
Myriam Roussigne
Sophia Kossida
Francois Amalric
Thomas Clouaire
Original Assignee
Endocube Sas
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocube Sas, Centre Nat Rech Scient filed Critical Endocube Sas
Application granted granted Critical
Publication of ATE451387T1 publication Critical patent/ATE451387T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
AT02796602T 2001-12-18 2002-12-10 Neue mit dem zelltod assoziierte proteine aus der thap familie und par4 verwandte signalwege, die bei der kontrolle von apoptosis involviert sind ATE451387T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34199701P 2001-12-18 2001-12-18
PCT/EP2002/014027 WO2003051917A2 (en) 2001-12-18 2002-12-10 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control

Publications (1)

Publication Number Publication Date
ATE451387T1 true ATE451387T1 (de) 2009-12-15

Family

ID=23339898

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02796602T ATE451387T1 (de) 2001-12-18 2002-12-10 Neue mit dem zelltod assoziierte proteine aus der thap familie und par4 verwandte signalwege, die bei der kontrolle von apoptosis involviert sind

Country Status (9)

Country Link
US (2) US7572886B2 (de)
EP (1) EP1458754B1 (de)
JP (2) JP2005527191A (de)
AT (1) ATE451387T1 (de)
AU (1) AU2002361385B2 (de)
CA (1) CA2471777A1 (de)
DE (1) DE60234713D1 (de)
ES (1) ES2337989T3 (de)
WO (1) WO2003051917A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051917A2 (en) 2001-12-18 2003-06-26 Endocube Sas Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
US7910314B2 (en) * 2002-03-01 2011-03-22 Roger Williams Hospital Shc protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
US20050004008A1 (en) * 2002-03-01 2005-01-06 Frackelton A. Raymond SHC proteins as therapeutic targets in proliferative diseases
US20040224408A1 (en) * 2002-12-10 2004-11-11 Jean-Philippe Girard THAP proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
EP1723428A2 (de) 2004-02-19 2006-11-22 Yale University Corporation Identifizierung von krebsprotein-biomarkern unter verwendung von proteomtechniken
JP2008502582A (ja) * 2004-06-18 2008-01-31 アンドキューブ ソシエタ パー アクシオン シンプリフィー ケモカイン結合タンパク質およびその使用方法
US20060094059A1 (en) * 2004-09-22 2006-05-04 Odyssey Thera, Inc. Methods for identifying new drug leads and new therapeutic uses for known drugs
EP1946117B1 (de) * 2005-11-11 2011-08-24 Roger Williams Hospital P66-shc als prädiktiver marker bei der krebsbehandlung
US8568980B2 (en) * 2009-01-27 2013-10-29 Mount Sinai School Of Medicine Nucleic acids, methods and kits for the diagnosis of DYT6 primary torsion dystonia
JP5719443B2 (ja) 2010-09-26 2015-05-20 ダ・ユー・エンタープライジズ、エルエルシー 組換え巨大分子製造方法
EA201590916A1 (ru) 2012-11-09 2016-02-29 Корнэлл Юниверсити Низкомолекулярные ингибиторы malt1
JP7863505B2 (ja) * 2019-12-17 2026-05-21 オリオニス バイオサイエンシズ，インコーポレイテッド 分子相互作用の検出
US11730750B2 (en) 2020-02-17 2023-08-22 University Of Kentucky Research Foundation Drugs for GRP78 cell surface translocation and Par-4 secretion

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US82206A (en) * 1868-09-15 William chesley
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8311018D0 (en) * 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0273085A1 (de) 1986-12-29 1988-07-06 IntraCel Corporation Verfahren zur Einführung fremder Nukleinsäuren in eukaryotische Zellen
WO1988006630A1 (en) 1987-03-02 1988-09-07 Genex Corporation Method for the preparation of binding molecules
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
IT1227907B (it) * 1988-12-23 1991-05-14 Eniricerche S P A Milano Sclav Procedimento per la sintesi di peptidi retro-inversi e nuovi intermediin tale procedimento
US5198346A (en) * 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5424186A (en) * 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DK0562025T3 (da) 1990-12-06 2001-06-18 Affymetrix Inc Forbindelser og deres anvendelse i en binær syntesestrategi
US5292646A (en) 1991-02-06 1994-03-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
US5270181A (en) * 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE69226871T3 (de) * 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5219089A (en) * 1992-03-12 1993-06-15 Chapco Carton Company Non-corrugated cardboard box construction
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
JP3537141B2 (ja) 1992-10-30 2004-06-14 ザ ゼネラル ホスピタル コーポレーション 新種蛋白質分離のための相互作用を用いる補捉システム
PT669929E (pt) * 1992-11-13 2007-04-30 Immunex Corp Ligando de elk, uma citoquina
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
FR2707296B1 (fr) 1993-07-09 1995-09-29 Genset Sa Procédé de synthèse d'acides nucléiques sur support solide et composés utiles notamment comme support solide dans ledit procédé.
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
CA2139065A1 (en) * 1994-12-23 1996-06-24 Eugenia Wang Apoptosis specific tp30 protein
US6221615B1 (en) * 1995-05-12 2001-04-24 Apoptosis Technology, Inc. Peptides and compositions which modulate apoptosis
US5897999A (en) * 1996-03-22 1999-04-27 The Johns Hopkins University Cancer drug screen based on cell cycle uncoupling
WO1997047321A1 (en) * 1996-06-14 1997-12-18 The Johns Hopkins University School Of Medicine Use of chimeric vaccinia virus complement control proteins to inhibit complement
US6242569B1 (en) * 1997-02-05 2001-06-05 Tularik, Inc. Regulators of apoptosis
US6191269B1 (en) * 1997-05-30 2001-02-20 The Regents Of The University Of California Selective induction of cell death by delivery of amino-terminal interleukin-1-α pro-piece polypeptide
US6340740B1 (en) * 1997-08-26 2002-01-22 Thomas Jefferson University Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use
AU758004B2 (en) * 1997-12-17 2003-03-13 Genset S.A. Extended cDNAs for secreted proteins
WO2000006728A2 (en) * 1998-07-28 2000-02-10 Incyte Pharmaceuticals, Inc. Phosphorylation effectors
JP2004507202A (ja) * 1999-03-31 2004-03-11 キュラジェン　コーポレイション ポリペプチドをコードするオープンリーディングフレームを含む核酸；「ｏｒｆｘ」
EP1074617A3 (de) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers für Synthese von ganzen-Länge cDNS und deren Anwendung
AU7680300A (en) 1999-08-18 2001-03-13 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Human dna sequences
AU2001234944A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20020082206A1 (en) * 2000-05-30 2002-06-27 Leach Martin D. Novel polynucleotides from atherogenic cells and polypeptides encoded thereby
WO2003051917A2 (en) 2001-12-18 2003-06-26 Endocube Sas Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
US20040224408A1 (en) 2002-12-10 2004-11-11 Jean-Philippe Girard THAP proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation

Also Published As

Publication number Publication date
CA2471777A1 (en) 2003-06-26
WO2003051917A3 (en) 2003-12-18
WO2003051917A2 (en) 2003-06-26
US20100021482A1 (en) 2010-01-28
US7572886B2 (en) 2009-08-11
JP2005527191A (ja) 2005-09-15
US20030186337A1 (en) 2003-10-02
DE60234713D1 (de) 2010-01-21
ES2337989T3 (es) 2010-05-03
AU2002361385B2 (en) 2009-11-19
EP1458754B1 (de) 2009-12-09
JP2010158248A (ja) 2010-07-22
AU2002361385A1 (en) 2003-06-30
EP1458754A2 (de) 2004-09-22

Similar Documents

Publication Publication Date Title
DE60234713D1 (de) Neue mit dem zelltod assoziierte proteine aus der thap familie und par4 verwandte signalwege, die bei der kontrolle von apoptosis involviert sind
DE60332239D1 (de) Neue chemokine bindende peptide, die die biologische aktivität dieser chemokine modulieren
ATE469981T1 (de) Tests auf proteinkinasen mit fluoreszierenden proteinsubstraten
DE69131249D1 (de) Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen
ATE176330T1 (de) Statistisch zufällige, pluripotente bio- oligomerenbank, eine methode solche zu synthetisieren und eine methode diese zu benützen
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
DK1049767T3 (da) En transgen kanin, der udtrykker et funktionelt humant lipoprotein(A)
PL377553A1 (pl) Peptydy oraz pokrewne cząsteczki modulujące aktywność czynnika wzrostu nerwów
DE60128216D1 (de) Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen
DE69931178D1 (de) Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2
PT1044197E (pt) Carboxamidas de piridilalcano, -alceno e -alcino substituidas por piperidinilo como agentes citostaticos e imunossupressores
BR9305617A (pt) Uso de isolados de bacillus thuringiensis para controlar pragas na familia dos afidideos
EP1572937A4 (de) Mit motiven transplantierte hybrid-polypeptide und verwendungen davon
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
WO2001064877A3 (en) Human schizophrenia gene
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
ATE307899T1 (de) Neue methode zum auffindenund bewerten biologisch aktiver moleküle
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
DE69836758D1 (de) Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
SI1465927T1 (sl) Protitelesa proti BAG3 za uporabo pri raziskavi, diagnostiki in terapiji bolezni, ki vključujejo celično smrt
EA200600561A1 (ru) Фармацевтический препарат для лечения шока
ATE301194T1 (de) Beta-defensine
WO2003093305A3 (en) Teneurin c-terminal associated peptides (tcap) and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties